XGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exagen Inc (XGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising growth in revenue and gross margin, the recent price stagnation, lack of significant trading signals, and analyst price target reductions suggest limited immediate upside. The stock may be worth monitoring for future entry points, but it does not currently present a compelling buying opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 71.989, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 3.867 and 4.068, while support levels are at 3.218 and 3.017. The current price of 3.79 is near the first resistance level, indicating limited immediate upside.
Revenue increased by 37.87% YoY in Q3 2025, and gross margin improved by 4.68%. Volume growth of 11% in 2025 and new territory expansions indicate potential for future growth.
The stock has dropped over 60% following Q3 results, reflecting market concerns.
In Q3 2025, revenue increased by 37.87% YoY to $17.24M. Net income improved by 40.95% YoY but remains negative at -$7.09M. EPS increased by 10.71% YoY to -0.31. Gross margin improved to 58.43%, up 4.68% YoY.
Analysts maintain a Buy rating but have lowered price targets significantly over the past months. The current price target range is $8-$10, down from previous targets of $13-$18. Analysts cite near-term pricing headwinds but acknowledge potential for double-digit revenue growth in 2026.
